Brief: Valbiotis: Positive Results From Phase IIa Clinical Study Of Valedia

Valbiotis SA

03/07/2019 17:32

July 3 (Reuters) - Valbiotis SAS  ALVAL.PA :
    * VALBIOTIS ANNOUNCES POSITIVE RESULTS FROM THE PHASE IIA CLINICAL STUDY OF VALEDIA®, NOW
THE
FIRST PRODUCT PROVEN EFFECTIVE IN PEOPLE WITH PREDIABETES
    * VALEDIA SIGNIFICANTLY REDUCED FASTING AND POST-PRANDIAL BLOOD GLUCOSE LEVELS, TWO RISK
FACTORS
FOR TYPE 2 DIABETES, COMPARED TO PLACEBO.
    * VALEDIA SIGNIFICANTLY REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCE, COMPARED TO PLACEBO.
    * VALEDIA IS NOW FIRST CLINICALLY VALIDATED PRODUCT DESIGNED FOR PEOPLE WITH PREDIABETES
THAT
REDUCES RISK FACTORS FOR TYPE 2 DIABETES
    * COMMERCIALIZATION IS PLANNED FOR 2021, AS PREVIOUSLY ANNOUNCED.

Source text for Eikon:  ID:nBw3XbmV5a 
Further company coverage:  ALVAL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))